Superworth

Halozyme Therapeutics price to book ratio HALO

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
99.3×
10-year median
26.1×
Against its 10-year history
97th
percentile: 0 is its lowest day, 100 its highest
10-year range
8.3× to 172×
Peer median
5.1×

Halozyme Therapeutics' price to book ratio is 99.3× as of Oct 23, 2026.

That is above its ten-year median of 26.1×, higher than on 97% of days in the last ten years.

Over that time it ranged from 8.3× in May 2019 to 172× in Feb 2026.

The median for 10 biotech stocks of a similar size is 5.1×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far99.3×16.2×172×
202516.1×13.3×27.4×
202413.5×12.8×63.1×
202319.6×19.6×87.3×
202279.3×16.3×82.9×
202120.1×16.2×97.8×
202058.3×10.6×67.8×
201910.7×8.3×11.6×
20188.6×8.4×40.0×
201739.8×29.0×43.5×
2016110×25.2×158×
201569.8×3.6×83.6×
201430.2×14.3×30.2×
2013131×11.9×131×
201214.6×6.4×131×
201136.4×31.0×44.2×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

CompanyPrice to book ratio
HALOHalozyme Therapeutics99.3×
NBIXNeurocrine Biosciences3.9×
EXELExelixis8.7×
TECHBIO-TECHNE5.4×
RGENRepligen4.7×
KRYSKrystal Biotech6.8×
INCYIncyte3.7×
UTHRUnited Therapeutics3.9×
ALNYAlnylam Pharmaceuticals22.1×
ONCBeOne Medicines8.3×
REGNRegeneron Pharmaceuticals2.6×
Peer median5.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.